Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week Trial to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers in a Naturalistic Environment

This study is to see if a new nicotine replacement therapy safely helps people to quit smoking if it is used the way it would be if it were sold at the pharmacy and used at home. Approximately 1500 subjects will be enrolled into the study. The study will require participants to use the treatment for 12 weeks and there will be a 14-week follow-up period. The study will be conducted in approximately 20 pharmacies across the United States.

At the first visit to the pharmacy, participants will be asked some questions to see if they are eligible to participate. Participants will be asked to sign a consent form if they agree to participate. Participants will answer some more questions, and blow into a machine to measure their carbon monoxide (CO) levels to make sure they qualify for the trial. Participants will be asked to go to a nearby dentist who will look at their mouths. Participants will go back to the pharmacy and if they qualify, they will be given a supply of their assigned treatment. They will have an equal chance of receiving a treatment that has a drug in it or one that has no drug in it. They will be given a diary to keep track of how much of the treatment they use.

Subjects will go to the pharmacy four more times to hand in their diaries and blow into a machine that will measure their CO levels. At the last visit, subjects will have their mouths examined by a dentist again to have their mouth checked.

Subjects will receive four telephone calls during the study where they will be asked some questions.

After the 12 week treatment period, subjects will receive two to three more telephone calls, where they will be asked to answer some questions. Participants may be asked to come back to the pharmacy two more times to blow into the carbon monoxide machine again.

Study Overview

• Status: Terminated
• Conditions: Tobacco Dependence
• Intervention / Treatment: Drug: Placebo; Drug: Nicotine

Detailed Description

This trial is a multi-center, randomized, double blind, placebo-controlled parallel group study to measure the efficacy and safety of a new nicotine replacement therapy for smoking cessation in a naturalistic environment. Subjects will be randomized in a 2:1 ratio (active to placebo). It is anticipated that data from about 450 in the active treatment group at Week 12 will be required for the safety analysis. In order to obtain that number of subjects, approximately 1500 subjects will need to be enrolled into the Use phase of the study, 1000 in the active arm and 500 in the placebo arm.

Based on the directions for use on the Drug Facts label, the study will include six weeks of full study drug treatment and then six weeks of progressive tapering drug treatment (Weeks 1-12). There will be a 14-week post-use follow up period.

This trial will be conducted in three sequential phases: Enrollment (baseline), Use and Post-use Follow-up. The Enrollment Phase will be conducted in approximately 20 pharmacies in nine diverse geographical areas in the continental United States. Subjects who qualify to participate in the study will be given three units of investigational product, a subject diary for tracking investigational product use and a medical problems worksheet to assist in the collection of AE information. Subjects will also be given a small hand counter and will be encouraged to use it to help keep track of the number of doses they use each day. Subjects will also be given a card with contact information for the pharmacy and study nurses. Where needed, the subject can also speak with the study physician.

During the Use Phase, the collection of data related to efficacy will be accomplished during four return visits to the pharmacy (at weeks 2, 4, 6 and 12). Self-reported abstinence will be verified by carbon monoxide (CO) measurements obtained at each pharmacy visit. Subjects will be given a subject use diary at each follow-up and re-supply visit and completed diaries will be collected each time the subject returns to the pharmacy. Subjects can return to the pharmacy for additional supplies at any time during their participation. Empty units will be returned during these visits.

Safety data will be collected during four telephone interviews, conducted by trained nurse interviewers, at weeks 2, 4, 6 and 12. If a subject reports an adverse event during a visit (return visit or resupply visit), this information will be immediately forwarded to the nurse interviewers for follow-up. Subjects may also initiate a call to the study nurses themselves to discuss health problems. All AE information collected will be reviewed by a physician as the adverse events are collected. A standardized visual mouth examination will be conducted by trained dentists at the enrollment visit and at the Week 12 return visit.

During the Post-use Follow-up period, self-reported efficacy and safety data will be collected during two telephone interviews initiated by trained nurse interviewers (at weeks 16 and 26). Subjects reporting abstinence since the last visit or abstinence for the prior seven days during these two interviews will be asked to return to the pharmacy to verify abstinence with an exhaled CO measurement. An additional telephone interview will be conducted between Week-12 and Week-16, by trained nurse interviewers, who will administer the End of Treatment questions to those subjects who have reported the following product use behavior that are inconsistent with the directions on the Drug Facts label: Use of more than 64 doses in a 24-hour period at least one time or use of more than 4 doses per hour at least one time based on the diary or their self report.

• Study Type: Interventional
• Enrollment (Actual): 257
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Muscle Shoals, Alabama, United States, 35661
      • Avalon Discount Drugs
  • California
    • Oceanside, California, United States, 92054
      • Coast Compounding Pharmacy
  • Georgia
    • Griffin, Georgia, United States, 30224
      • Wynn's Pharmacy, Inc.
  • Kansas
    • Overland Park, Kansas, United States, 64116
      • Stark Pharmacy
  • Minnesota
    • Anoka, Minnesota, United States, 55303
      • Goodrich Pharmacy
    • Elk River, Minnesota, United States, 55330
      • Goodrich Pharmacy
    • St. Francis, Minnesota, United States, 55070
      • Goodrich Pharmacy
    • St. Louis Park, Minnesota, United States, 55426
      • Cub Pharmacy #1924
  • Mississippi
    • Clarksdale, Mississippi, United States, 38614
      • Medicap Pharmacy
    • Holly Springs, Mississippi, United States, 38635
      • Liddy's Health Mart
  • Missouri
    • Savannah, Missouri, United States, 64485
      • Countryside Pharmacy
  • New Mexico
    • Albuquerque, New Mexico, United States, 87110
      • Phil's Pills
  • North Carolina
    • Raleigh, North Carolina, United States, 27609
      • Kerr Drug
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States, 18015
      • Family Prescription Center
  • Texas
    • Hillsboro, Texas, United States, 76645
      • T.B. Bond Pharmacy
    • Houston, Texas, United States, 77070
      • Inwood Pharmacy
    • Longview, Texas, United States, 75602
      • Louis Morgan Drug #1
    • Tyler, Texas, United States, 75701
      • Brick Street Pharmacy
  • Virginia
    • Montpelier, Virginia, United States, 23192
      • Montpelier Pharmacy, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects must be males or females 18 years of age or older who currently smoke cigarettes and are willing to stop smoking

Exclusion Criteria:

• Subjects must not have a recent history of unstable angina, myocardial infarction or stroke
• They must not have a suspected malignant and/or erosive oral lesion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; 0 mg Oral NRT, up to 4 times per hour for 12 weeks	Drug: Placebo; Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks; Other Names: Not marketed
Experimental: Nicotine; 1 mg Oral NRT, up to 4 times per hour for 12 weeks	Drug: Nicotine; Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks; Other Names: Not yet marketed

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Continuous Smoking Abstinence	Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6.	through Week 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Continuous Smoking Abstinence	Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26.	through Week 26
Number of Participants With 7-day Point Prevalence Abstinence	Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26.	through Week 26
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 1
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 2
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 3
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 4
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 5
Mean Number of Daily Doses	Mean number of daily doses by study week.	Week 6
Percentage of Participants With High Dosage	Percentage of participants who used more than 64 doses in any one-day period.	within 12 Weeks
Percentage of Participants With High Usage	Percentage of participants who used more than four doses in any one-hour period.	within 12 Weeks
Highest Rating of Desire/Urge to Smoke on a Categorical Scale	Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Irritability/Frustration/Anger on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Restlessness on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Difficulty Concentrating on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Anxiety on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Insomnia on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Highest Rating of Increased Appetite on a Categorical Scale	Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so.	within 12 Weeks
Participant Score for General Perception of the Product	Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.	through Week 12
Participant Score for Product Effectiveness in Dealing With Cravings	Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective.	through 12 Weeks
Participant Score for Speed of Action	Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.	through 12 Weeks
Participant Score for Change in Perception	Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.	through 12 Weeks
Participant Score for Product Convenience	Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.	through 12 Weeks

Collaborators and Investigators

• Sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
• Collaborators: GlaxoSmithKline; McNeil AB
• Investigators: Study Director: Daniel Qi, MD, McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (Actual): April 1, 2011
• Study Completion (Actual): June 1, 2011

Study Registration Dates

• First Submitted: February 14, 2011
• First Submitted That Met QC Criteria: February 14, 2011
• First Posted (Estimate): February 15, 2011

Study Record Updates

• Last Update Posted (Estimate): April 23, 2012
• Last Update Submitted That Met QC Criteria: March 29, 2012
• Last Verified: March 1, 2012

More Information

Terms related to this study

• Keywords: Smoking Cessation; Tobacco Use Disorder
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Tobacco Use Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: A6431112